# Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer

> **NCT00577356** · PHASE2 · TERMINATED · sponsor: **Benaroya Research Institute** · enrollment: 6 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Docetaxel
- **BIOLOGICAL:** CG1940/CG8711

## Key facts

- **NCT ID:** NCT00577356
- **Lead sponsor:** Benaroya Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Safety reasons, though no safety issues arose.
- **Last updated:** 2011-01-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00577356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00577356, "Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00577356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*